knowledge -WSS

knowledge

author：comprehensive 2025-09-29 16:35:55 - browse：43796

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Copay coupons to count toward deductibles, after Biden court move

entertainment

WSS

New brain studies show LSD's effects on the brain in full color

Snowpack in the West is melting rapidly. Where will all that extra water go?

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Test for long Covid? Researchers find new clue in blood samples

New brain studies show LSD's effects on the brain in full color

focus

knowledge

knowledge

The high cost of giving birth even with insurance

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

Virginia high school admissions case could be legal follow

How digital therapeutics firms are pivoting after Pear's bankruptcy

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Dobbs anniversary: the lost opportunity of abortion as health care

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Virginia high school admissions case could be legal follow

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

explore

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

Campaign finance charge dropped from case against Sam Bankman

Readout Newsletter: Merck, J&J, and long Covid

5 wounded, 2 critically, in Michigan shopping center shooting

AI generated plenty of interest at JPM but not a lot of trust

Snowpack in the West is melting rapidly. Where will all that extra water go?

hotspot

entertainment

knowledge

explore